Request Demo

Last update 23 Jan 2025

Hepatic Epithelioid Haemangioendothelioma

Last update 23 Jan 2025

Basic Info

Synonyms-

Introduction-

Drugs associated with Hepatic Epithelioid Haemangioendothelioma

Peginterferon Alfacon-2(Beijing Kawin Technology)

Target

IFNAR

Mechanism

IFNAR agonists [+2]

Active Org.

Beijing Kawin Technology Share-Holding Co., Ltd.

Originator Org.

Beijing Kawin Technology Share-Holding Co., Ltd.

Active Indication

Hepatitis C [+3]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date28 Jun 2018

Clinical Trials associated with Hepatic Epithelioid Haemangioendothelioma

CTR20243240

/ Not yet recruitingPhase 2

培集成干扰素α2注射液治疗肝上皮样血管内皮瘤的多中心、单臂、随机、开放的Ⅱa期临床研究

[Translation] A multicenter, single-arm, randomized, open-label phase Ⅱa clinical study of interferon α2 injection in the treatment of hepatic epithelioid hemangioendothelioma

主要目的初步探索培集成干扰素α-2注射液在肝上皮样血管内皮瘤患者的疗效。探索培集成干扰素α-2注射液治疗肝上皮样血管内皮瘤患者的II期推荐剂量（RP2D）。次要目的探索培集成干扰素α-2注射液在肝上皮样血管内皮瘤患者的药代动力学（PK）和药效学特征。观察培集成干扰素α-2注射液治疗肝上皮样血管内皮瘤患者的安全耐受性。观察培集成干扰素α-2注射液治疗肝上皮样血管内皮瘤患者的免疫原性。

[Translation]

Primary objective To preliminarily explore the efficacy of peginterferon α-2 injection in patients with hepatic epithelioid hemangioendothelioma. To explore the phase II recommended dose (RP2D) of peginterferon α-2 injection in the treatment of patients with hepatic epithelioid hemangioendothelioma. Secondary objective To explore the pharmacokinetic (PK) and pharmacodynamic characteristics of peginterferon α-2 injection in patients with hepatic epithelioid hemangioendothelioma. To observe the safety and tolerability of peginterferon α-2 injection in the treatment of patients with hepatic epithelioid hemangioendothelioma. To observe the immunogenicity of peginterferon α-2 injection in the treatment of patients with hepatic epithelioid hemangioendothelioma.

Start Date-

Sponsor / Collaborator

Beijing Kawin Technology Share-Holding Co., Ltd.

NCT06541652

/ RecruitingNot ApplicableIIT

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Start Date26 Mar 2024

Sponsor / Collaborator

Fédération Francophone de la Cancérologie Digestive

ChiCTR2200060969

/ SuspendedNot ApplicableIIT

Treatment of Hepatic Epithelioid Hemangioendothelioma: A single-Institution Experience

Start Date01 Jun 2022

Sponsor / Collaborator-

100 Clinical Results associated with Hepatic Epithelioid Haemangioendothelioma

100 Translational Medicine associated with Hepatic Epithelioid Haemangioendothelioma

0 Patents (Medical) associated with Hepatic Epithelioid Haemangioendothelioma

347

Literatures (Medical) associated with Hepatic Epithelioid Haemangioendothelioma

01 Feb 2025·Archivos Argentinos de Pediatria

Liver transplantation for primary liver tumors in pediatrics. A case series

Article

Author: Varela, Mariana ; Fauda, Martín ; Selzer Soria, Erika M ; Lagues, Cecilia ; González Campaña, Ariel ; Malla, Ivone ; Siaba Serrate, Alejandro

Primary liver tumors are an increasing indication for pediatric liver transplantation. Here we report the cases of 10 patients who underwent liver transplantation for primary liver tumors in our hospital, from 2001 to date. Up to 2011, 1 transplant due to hepatoblastoma was done out of 117 liver transplants (0.8%). Since 2012, there were 9 patients out of 141 (6.4%) (5 due to hepatoblastoma, 2 due to hepatocellular carcinoma, 1 due to hepatic epithelioid hemangioendothelioma, and 1 due to hepatic mesenchymal hamartoma). Follow-up: 13.2 months (median); age at transplantation: living 4.7 years (median); weight: 17.6 kg (median). Eighty percent of patients received grafts from living donors. No tumor recurrence was observed. Survival was 100% in the follow-up period. In our series, patients with primary liver tumors requiring transplantation showed an adequate course, even in the case of hepatocellular carcinoma, Related living donors liver transplantation shortened the time between the indication and the surgery.

01 Jan 2025·Journal of Clinical and Experimental Hepatology

Clinical, Histopathological, and Immunophenotypic Spectrum of Hepatic Epithelioid Hemangioendothelioma: Eight Years Data of a Tertiary Care Center from North India

Article

Author: Saikia, Uma N. ; Mitra, Suvradeep ; Saikia, Uma Nahar ; Saikia, Uma N ; Duseja, Ajay ; Das, Ashim ; Dey, Treshita ; Khosla, Divya ; Kaman, Lileshwar ; Dutta, Usha ; Barwad, Adarsh ; Kaur, Gunjangeet ; Chatterjee, Debajyoti

Background/AimsEpithelioid hemangioendothelioma (EHE) is an uncommon vascular tumor that commonly affects the liver. Hepatic EHE (HEHE) presents with variable clinical and histopathological features. We describe detailed clinico-histopathological features, differential diagnosis, and treatment outcomes of the cases of HEHE diagnosed in our center.MethodsAll cases of HEHE diagnosed in our institute in the last eight years (2016-2023) were reviewed (n = 8; 11 samples) (total 36 cases of EHE; 22.2%). The clinical features, radiology, histopathology, immunophenotype, molecular features, and treatment outcomes of all cases were evaluated.ResultsThe median age of presentation was 49.5 years with a female: male ratio of 7:1. Abdominal pain was the commonest presentation. Approximately two-thirds of the patients had multifocal lesions. Histopathology showed purely epithelioid, predominantly epithelioid, and predominantly spindle-cell morphology in 50%, 25%, and 25%, respectively. All cases showed typical myxohyaline/fibrous stroma and organized thrombi of the portal/central veins. CD31 was the most commonly used immunostain with positivity in all cases. CAMTA1 break-apart fluorescence in situ hybridization was positive in 75% of cases, while none showed TFE3 immunopositivity. Chemotherapy was the most commonly employed therapy (n = 5) followed by surgery (n = 2). The median duration of follow-up was 26 months. Five patients were alive with disease (two patients ≥3 years), one patient died of sudden cardiac death, and two patients were lost to follow-up. Two patients developed metastatic disease at follow-up.ConclusionsWe describe the clinico-histopathological features and differential diagnosis of HEHE. This appears to be the largest case series of HEHE from India.

01 Dec 2024·Asian Journal of Surgery

Rare hepatic epithelioid hemangioendothelioma with popliteal fossa metastases: A case report

Letter

Author: Wu, Dingwei ; Chen, Zhi ; Lin, Jiajun ; Wu, Zhengru

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis